Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-valent HPV vaccine versus Gardasil in girls aged 9 to 15 years
2010-023393-39Phase 3Completed
- Sponsor
- Sanofi Pasteur MSD S.N.C
- Start
- Nov 2010
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 2 more comparing 9-valent HPV vaccine with Gardasil comparator (2 arms). Primary endpoint: Geometric mean titers to HPV 16 and HPV 18. Started Nov 2010; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranogenital warts
Beyond the preview
Go deeper on 2010-023393-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023393-39.